Prelude Therapeutics Stock

preludetx.comHealthcareFounded: 2016Funding to Date: $95MM

Prelude Therapeutics is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.

Register for Details

For more details on financing and valuation for Prelude Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Prelude Therapeutics.

Register Today

Team

Management Team

Krishna Vaddi Ph.D
Founder, Chief Executive Officer & Board Member
David Mauro Ph.D
Chief Medical Officer
Peggy Scherle Ph.D
Chief Scientific Officer

Board Members

Krishna Vaddi Ph.D
Paul Friedman
Kelvin Neu
David Bonita

Other companies like Prelude Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$809.52MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$396.01MM
Sector
Last Round Est. Valuation
$400.53MM
Sector
Last Round Est. Valuation
$1.53B

News

Wilmington, Delaware-based clinical-stage biopharmaceutical company Prelude Therapeutics has raised $60 million in funding